Company

Arch Biopartners, Inc.

Headquarters: Toronto, ON, Canada

CEO: Mr. Richard Gabriel Muruve

TSXV: ARCH -7.50%

Market Cap

C$107.3 Million

CAD as of July 1, 2024

US$78.1 Million

Market Cap History

Arch Biopartners, Inc. market capitalization over time

Evolution of Arch Biopartners, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Arch Biopartners, Inc.

Detailed Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Arch Biopartners, Inc. has the following listings and related stock indices.


Stock: TSXV: ARCH wb_incandescent

Stock: OTC: ACHFF wb_incandescent

Details

Headquarters:

27 Street Clair Avenue East

P.O. Box 305

Toronto, ON M4T 2M5

Canada

Phone: 647 428 7031